---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-323651"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2026-07-29T20:05:43+00:00"
generated_at: "2026-07-29T20:07:45.410465+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Inhibikase Therapeutics exchanges 18M shares with RA Capital for pre-funded warrants

## Summary
- RA Capital exchanged 18,030,000 common shares for pre-funded warrants with $0.001 exercise price.
- Warrants are immediately exercisable, no expiration, with 9.99% beneficial ownership blocker (can increase to 19.99%).
- Issued under Section 3(a)(9) exemption from registration; no new cash raised.
- Exchange reduces outstanding shares but introduces potential dilution upon warrant exercise.

## SEC filing metadata
- accession: 0001193125-26-323651
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2026-07-29T20:05:43+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312526323651/0001193125-26-323651-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312526323651/d78217d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-323651
- JSON: https://secwatch.observer/filing/0001193125-26-323651.json
- Plain text: https://secwatch.observer/filing/0001193125-26-323651.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.